All AbMole products are for research use only, cannot be used for human consumption.
Bortezomib (PS-341) is a highly selective, reversible inhibitor of the 26S proteasome with a ki value of 6nM, which has shown high antimyeloma activity. Bortezomib caused comparable growth suppression in LNCaP-Pro5 and PC3M-Pro4 cells with an IC90 of 10 nM.
Cancer Lett. 2024 Apr 6;590:216861.
TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma
Bortezomib (PS-341) purchased from AbMole
Mol Ther Oncol. 2024 Apr 11;32(2):200802.
Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation
Bortezomib (PS-341) purchased from AbMole
Cell Death Differ. 2023 Mar 9.
Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα
Bortezomib (PS-341) purchased from AbMole
BMC Biol. 2023 Apr 7;21(1):75.
1, 6-Hexanediol regulates angiogenesis via suppression of cyclin A1-mediated endothelial function
Bortezomib (PS-341) purchased from AbMole
Sci Rep. 2020 Feb 25;10(1):3386.
Gender-specific Changes in Energy Metabolism and Protein Degradation as Major Pathways Affected in Livers of Mice Treated With Ibuprofen
Bortezomib (PS-341) purchased from AbMole
Cell Physiol Biochem. 2018;50(6):2341-2364.
Peperomin E Induces Promoter Hypomethylation of Metastatic-Suppressor Genes and Attenuates Metastasis in Poorly Differentiated Gastric Cancer.
Bortezomib (PS-341) purchased from AbMole
Int J Oncol. 2016 Oct;49(4):1469-78.
Metabotropic glutamate receptor 3 is involved in B-cell-related tumor apoptosis
Bortezomib (PS-341) purchased from AbMole
 . figure 9..jpg) |
Source | INTERNATIONAL JOURNAL OF ONCOLOGY (2016) . Figure 9. Bortezomib (M1686) was from Abmole Bioscience Inc. (Houston, TX, USA) |
| Method | FACS | |
| Cell Lines | B cells from CD19 cre/+Foxo1F/+ and CD19 cre/+Foxo1F/F mice | |
| Concentrations | 0.05 μg/ml | |
| Incubation Time | 24 h | |
| Results | The effect of Foxo1-defciency on cell apoptosis was approved by using B cells from CD19cre/+Foxo1F/+ and CD19cre/+Foxo1F/F (Fig. 9D). |
 . figure 5..jpg) |
Source | INTERNATIONAL JOURNAL OF ONCOLOGY (2016) . Figure 5. MBortezomib (M1686) was from Abmole Bioscience Inc. (Houston, TX, USA) |
| Method | FACS | |
| Cell Lines | SP2/0 cells | |
| Concentrations | 0, 0.05 and 0.25 μg/ml | |
| Incubation Time | 24 h | |
| Results | Low dose of bortezomib, frst-line drug in patients with newly diagnosed multiple myeloma, could effectively induce apoptosis and Grm3 expression (Fig. 5). |
| Cell Experiment | |
|---|---|
| Cell lines | Nine canine melanoma cell lines (CMM-1, CMM-2, ChMC, KMeC, LMeC, OMJ, OMS, OMK, and NML) |
| Preparation method | Cell growth inhibition assay Nine canine melanoma cell lines (CMM-1, CMM-2, ChMC, KMeC, LMeC, OMJ, OMS, OMK, and NML) were cultured in 96-well plates (2 *102 cells/well) for 24 h in cDMEM and treated with different concentrations of bortezomib (0–100 nM) for 72 h. Cell viability was then measured by a WST-1 cell proliferation assay kit (Takara) and the half maximal inhibitory concentration (IC50) of bortezomib for each cell line was calculated using the GraphPad Prism software (GraphPad Software). |
| Concentrations | 0–100 nM |
| Incubation time | 72 h |
| Animal Experiment | |
|---|---|
| Animal models | CMM-1 cells in xenograft mouse models |
| Formulation | 100 µL PBS containing 4.2% DMSO |
| Dosages | 0.8mg/kg twice weekly |
| Administration | intravenous(IV) injections |
| Molecular Weight | 384.24 |
| Formula | C19H25BN4O4 |
| CAS Number | 179324-69-7 |
| Solubility (25°C) | DMSO 72 mg/mL |
| Storage | 2-8°C, protect from light |
[2] Ashley J Chui, et al. Science. N-terminal degradation activates the NLRP1B inflammasome
| Related Proteasome Products |
|---|
| Proteasome inhibitor IX
Proteasome inhibitor IX (PS-IX; AM114) is a Chalcone derivative and a chymotrypsin-like activity of the 20S proteasome inhibitor with an IC50 value of ~1 μM. |
| NIC-0102
NIC-0102 is an orally potent proteasome inhibitor (pIC50=7.55) that specifically inhibits NLRP3 inflammasome activation.NIC-0102 showed potent anti-inflammatory effects in vivo in a DSS-induced ulcerative colitis model. In addition, NIC-0102 inhibited the production of pro-IL-1β. |
| Ac-WLA-AMC
Ac-WLA-AMC is a specific 20S constitutive proteasome β5 fluorogenic substrate. |
| Ac-Nle-Pro-Nle-Asp-AMC
Ac-Nle-Pro-Nle-Asp-AMC is a specific substrate for 26S proteasome. |
| PR-39
PR-39, a natural proline- and arginine-rich antibacterial peptide, is a noncompetitive, reversible and allosteric proteasome inhibitor. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
